Targeting Pancreatic Stellate Cells in Cancer

Jonas Schnittert, Ruchi Bansal, Jai Prakash (Corresponding Author)

Research output: Contribution to journalReview articleAcademicpeer-review

3 Citations (Scopus)

Abstract

Pancreatic stellate cells (PSCs) are the major contributor to the aggressive, metastatic, and resilient nature of pancreatic ductal adenocarcinoma (PDAC), which has a poor prognosis with a 5-year survival rate of 8%. PSCs constitute more than 50% of the tumor stroma in PDAC, where they induce extensive desmoplasia by secreting abundant extracellular matrix (ECM) proteins. In addition, they establish dynamic crosstalk with cancer cells and other stromal cells, which collectively supports tumor progression via various inter- and intracellular pathways. These cellular interactions and associated pathways may reveal novel therapeutic opportunities against this unmet clinical problem. In this review article, we discuss the role of PSCs in inducing tumor progression, their crosstalk with other cells, and therapeutic strategies to target PSCs.

Original languageEnglish
Pages (from-to)128-142
Number of pages15
JournalTrends in cancer
Volume5
Issue number2
DOIs
Publication statusPublished - 1 Feb 2019

Fingerprint

Pancreatic Stellate Cells
Neoplasms
Adenocarcinoma
Extracellular Matrix Proteins
Stromal Cells
Therapeutics

Keywords

  • cancer-associated fibroblasts
  • desmoplasia
  • pancreatic cancer
  • pancreatic ductal adenocarcinoma
  • tumor stroma

Cite this

Schnittert, Jonas ; Bansal, Ruchi ; Prakash, Jai. / Targeting Pancreatic Stellate Cells in Cancer. In: Trends in cancer. 2019 ; Vol. 5, No. 2. pp. 128-142.
@article{333a14c1859c4e2b8d325e60ed49ae29,
title = "Targeting Pancreatic Stellate Cells in Cancer",
abstract = "Pancreatic stellate cells (PSCs) are the major contributor to the aggressive, metastatic, and resilient nature of pancreatic ductal adenocarcinoma (PDAC), which has a poor prognosis with a 5-year survival rate of 8{\%}. PSCs constitute more than 50{\%} of the tumor stroma in PDAC, where they induce extensive desmoplasia by secreting abundant extracellular matrix (ECM) proteins. In addition, they establish dynamic crosstalk with cancer cells and other stromal cells, which collectively supports tumor progression via various inter- and intracellular pathways. These cellular interactions and associated pathways may reveal novel therapeutic opportunities against this unmet clinical problem. In this review article, we discuss the role of PSCs in inducing tumor progression, their crosstalk with other cells, and therapeutic strategies to target PSCs.",
keywords = "cancer-associated fibroblasts, desmoplasia, pancreatic cancer, pancreatic ductal adenocarcinoma, tumor stroma",
author = "Jonas Schnittert and Ruchi Bansal and Jai Prakash",
year = "2019",
month = "2",
day = "1",
doi = "10.1016/j.trecan.2019.01.001",
language = "English",
volume = "5",
pages = "128--142",
journal = "Trends in cancer",
issn = "2405-8025",
publisher = "Cell Press",
number = "2",

}

Targeting Pancreatic Stellate Cells in Cancer. / Schnittert, Jonas; Bansal, Ruchi; Prakash, Jai (Corresponding Author).

In: Trends in cancer, Vol. 5, No. 2, 01.02.2019, p. 128-142.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - Targeting Pancreatic Stellate Cells in Cancer

AU - Schnittert, Jonas

AU - Bansal, Ruchi

AU - Prakash, Jai

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Pancreatic stellate cells (PSCs) are the major contributor to the aggressive, metastatic, and resilient nature of pancreatic ductal adenocarcinoma (PDAC), which has a poor prognosis with a 5-year survival rate of 8%. PSCs constitute more than 50% of the tumor stroma in PDAC, where they induce extensive desmoplasia by secreting abundant extracellular matrix (ECM) proteins. In addition, they establish dynamic crosstalk with cancer cells and other stromal cells, which collectively supports tumor progression via various inter- and intracellular pathways. These cellular interactions and associated pathways may reveal novel therapeutic opportunities against this unmet clinical problem. In this review article, we discuss the role of PSCs in inducing tumor progression, their crosstalk with other cells, and therapeutic strategies to target PSCs.

AB - Pancreatic stellate cells (PSCs) are the major contributor to the aggressive, metastatic, and resilient nature of pancreatic ductal adenocarcinoma (PDAC), which has a poor prognosis with a 5-year survival rate of 8%. PSCs constitute more than 50% of the tumor stroma in PDAC, where they induce extensive desmoplasia by secreting abundant extracellular matrix (ECM) proteins. In addition, they establish dynamic crosstalk with cancer cells and other stromal cells, which collectively supports tumor progression via various inter- and intracellular pathways. These cellular interactions and associated pathways may reveal novel therapeutic opportunities against this unmet clinical problem. In this review article, we discuss the role of PSCs in inducing tumor progression, their crosstalk with other cells, and therapeutic strategies to target PSCs.

KW - cancer-associated fibroblasts

KW - desmoplasia

KW - pancreatic cancer

KW - pancreatic ductal adenocarcinoma

KW - tumor stroma

UR - http://www.scopus.com/inward/record.url?scp=85060848346&partnerID=8YFLogxK

U2 - 10.1016/j.trecan.2019.01.001

DO - 10.1016/j.trecan.2019.01.001

M3 - Review article

VL - 5

SP - 128

EP - 142

JO - Trends in cancer

JF - Trends in cancer

SN - 2405-8025

IS - 2

ER -